The Cell & Gene Therapy industry is generating more data than ever before.
Every week brings new clinical trial results, funding rounds, manufacturing expansions, regulatory milestones, licensing agreements, and strategic partnerships. Yet many executives still spend hours collecting information from multiple sources before making a decision.
Today, the global CGT ecosystem includes more than 1,300 companies, thousands of active clinical programs, hundreds of manufacturing facilities, and a rapidly growing pipeline of advanced therapies targeting cancer, rare diseases, genetic disorders, autoimmune conditions, and neurological diseases.
The challenge?
Most decision-makers are still collecting information from multiple databases, company announcements, investor reports, regulatory updates, and clinical trial registries.
That’s why we developed the Cell & Gene Therapy Intelligence Dashboard — a single platform designed to help users track the companies, technologies, investments, clinical trials, and manufacturing capabilities shaping the future of advanced therapies.
The dashboard provides intelligence across:
✓ 1,300+ Cell & Gene Therapy companies
✓ Clinical trial activity across development stages
✓ Manufacturing and CDMO intelligence
✓ Funding rounds and investment trends
✓ M&A and licensing activities
✓ Strategic partnerships and collaborations
✓ Competitive benchmarking
✓ Market opportunity analysis
Industry Leaders Tracked on the Platform
Our dashboard continuously tracks leading CGT innovators and commercial players.
| Company | CGT Focus | Key Product |
|---|---|---|
| Novartis | CAR-T Cell Therapy | Kymriah |
| Bristol Myers Squibb | CAR-T Oncology | Abecma, Breyanzi |
| Vertex Pharmaceuticals | Gene Editing | Casgevy |
| CRISPR Therapeutics | Gene Editing | CRISPR-Based Therapies |
| Regeneron Pharmaceuticals | Genetic Medicine | Genetic Medicine Pipeline |
Request a Demo: https://www.towardshealthcare.com/cell-gene-intelligence-platform
These companies are shaping the future of the industry through innovation, commercialization, strategic partnerships, and manufacturing investments.
Our team has built a comprehensive Cell & Gene Therapy Intelligence Dashboard to help pharmaceutical companies, biotech firms, investors, consultants, CDMOs, and healthcare decision-makers navigate one of the fastest-evolving sectors in healthcare.
Exclusive Intelligence Resources Included with Dashboard Access
Gain access to premium Cell & Gene Therapy intelligence designed to help decision-makers identify opportunities, benchmark competitors, and stay ahead of market shifts.
Cell & Gene Therapy Market Outlook Report
Customized forecast:
2026 onwards based on your requirement.
Includes:
• Market size analysis
• Growth drivers
• Emerging technologies
• Competitive landscape
Top 100 CGT Companies Report
Includes:
• Company profiles
• Pipeline analysis
• Innovation benchmarking
• Strategic activities
CGT Investment Landscape Report
Includes:
• Funding trends
• M&A activity
• Investor movement
• Opportunity analysis
From pharma innovations to competitive movements, track everything in one intelligent dashboard built for decision makers, Access the dashboard: https://www.towardshealthcare.com/access-dashboard
Clinical Trial Benchmark Report
Includes:
• Trial success trends
• Development timelines
• Clinical performance analysis
Access the Cell & Gene Therapy Intelligence Dashboard and unlock the insights shaping the future of advanced therapies.
Quick Contact Details
Complete Cell & Gene Therapy intelligence; from discovery to commercialization available in one platform. For quick call contact us at:
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04